Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 3 of 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Establishment of Reference Interval for M2BPGI Glyco-Biomarker in the Serum of Mongolian People
    (Mongolian National University of Medical Sciences, 2020-12-29) ; ; ; ;
    Objectives: Establishment of reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people. Methods: Serum analysis for M2BPGI glyco-biomarker, hepatitis virus markers, and AFP analysis were performed using a fully automated chemiluminescence immunoassay analyzer. Non-parametric methods were used for establishment of reference interval according to the guideline of the Clinical Laboratory Standards Institute. Statistical analysis was done by using SPSS ver. 20.0; SPSS Inc., Chicago, IL software. Results: Total of 3384 people were involved in this study. Of the total participants, 40% were overweight and 31.3% were obese. Also, of the population 10.1 percent were positive for HBsAg, 17 percent were positive for Anti-HCV, and 1.1 percent had co infection of both HBV and HCV. A total of the 316 individuals met the inclusion criteria for reference interval establishment and 77 (24.4%) of them were men and 239 (75.6%) were women. The reference interval of M2BPGI glyco-biomarker for men was 0.883 ± 0.311C.O.I and for women was 0.951 ± 0.411C.O.I. Conclusion: It is determined that the reference interval for M2BPGI glyco-biomarker in the serum of relatively healthy Mongolian people was 0.936 ± 0.391C.O.I.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Results of the National Study of CLEIA Method for the Prevalence of HBV and HCV in the 40-64 Age Population of Mongolia
    (Mongolian National University of Medical Sciences, 2019-09-25) ; ; ; ;
    Objective: Using high-sensitivity test results of CLEIA we aimed to investigate the prevalence of hepatitis B and C virus, and compare levels of AST, ALT, M2BPGI in the Mongolian population in the age between 40-64. Methods: In order to reflect the administrative and geographical features of Mongolia, the sampling was done at three levels: urban, province center, and rural. Immunological test was measured by chemiluminescence enzyme immunoassay (CLEIA). The statistical package for the social sciences (SPSS) version 25 was used for the statistical analyses. Results: The survey covered 3196 people. 71.8 percent of the patients surveyed had a negative in hepatitis test. 10.1 percent had a positive HBsAg test. 17 percent had a positive anti-HCV test. 1.1 percent had both a positive both HBsAg and anti-HCV (<.0001). AST and ALT increased more frequently during co-infection. M2BPGI protein average level in the non-infected group was 1.00 C.O.I, in the HBsAg positive group 1.65 C.O.I, in the anti-HCV positive group 1.83 C.O.I, and in the co-infection group 1.87 C.O.I (<.0001). Conclusion:10.1 percent of 40-64year-olds in Mongolia were infected with hepatitis B virus, and 17 percent had Hepatitis C virus and 1.1 percent had hepatitis B and C virus co-infections. Serum M2BPGi is increasing in hepatitis C virus infection and in co-infection.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Prevalence, characteristics, and virologic correlations of hepatitis delta (D) among patients with hepatitis B surface antigen in Mongolia
    (National Center for Global Health and Medicine (JST), 2024-04) ;
    Rokuhara, Akinori
    ;
    Sugiyama, Masaya
    ;
    Dorj, Sumiya
    ;
    Barsuren, Batnasan
    Clinical and biochemical features of hepatitis delta virus (HDV) infections in Mongolia remain largely unknown. We aimed to investigate the clinical characteristics of HDV patients in Mongolia using several markers. The 143 hepatitis B surface antigen (HBsAg)-positive patients were divided into 122 HDV-positive and 21 HDV-negative patients by HDV RNA positivity. Subgroup analysis was performed between hepatitis B e antigen (HBeAg)-positive and -negative HDV-positive patients. Liver function, quantitative HBsAg (qHBsAg), anti-HDV Immunoglobulin (Ig) M, Mac-2 binding protein glycosylation isomer (M2BPGi), hepatitis B virus (HBV) DNA level, and HDV RNA level were tested. HDV RNA was positive in 85.3% (122/143) of patients showing anti-HDV IgG. Liver disease activity was higher in HDV-positive patients than in HDV-negative patients. The HDV-positive group included a higher proportion of patients with high qHBsAg and M2BPGi levels (p < 0.001). The positivity rate for anti-HDV IgM was significantly higher in the HDV-positive group (p < 0.001). HDV RNA levels showed an inverse correlation with qHBsAg levels in HBeAg-positive-HDV-positive patients (r = -0.49, p = 0.034), and a positive correlation with qHBsAg levels in HBeAg-negative patients (r = 0.35, p < 0.001). Hepatitis B virus (HBV) DNA and HDV RNA levels did not show any correlation. M2BPGi levels likewise did not correlate with HDV RNA levels. A high positivity rate for HDV RNA was observed for HBV patients in Mongolia using the highly sensitive HDV RNA assay. The positivity rate for anti-HDV IgM was high in HDV RNA-positive patients. Severity of liver disease and M2BPGi levels were both high in the HDV RNA-positive group.
    Scopus© Citations 2